Project: Advanced modelling of Parkinson’s disease with three-dimensional human midbrain organoids
Acronym | 3DPD (Reference Number: 124) |
Duration | 01/04/2016 - 31/03/2019 |
Project Topic | One of the main limitations in neuroscience and in the modeling of neurodegenerative diseases is the lack of advanced experimental in vitro models that truly recapitulate the complexity of the human brain. Therefore, it is the aim of the here proposed research project to generate brain-like organoids that resemble the human midbrain and their integration into a multifunctional lab-on-a-chip device. We will focus on Parkinson’s disease, which is the second most common neurodegenerative disease. The midbrains-on-achip will be generated from induced pluripotent stem cells derived from Parkinson’s disease patients that carry defined disease causing mutations as well as from idiopathic patients. This will allow us to elucidate how Parkinson’s disease imparts architectural remodelling, dopamine release and network formation of the midbrain tissue. The successful cultivation of in vitro midbrain organoids in a micro-analytical analysis platform will yield substantial insights and open new avenues for exploring the mechanisms of onset and progression under physiologically relevant measurement conditions. Moreover by the usage of microfluidics devices the whole approach is cost-effective and suitable for screening purposes. We hypothesize that Parkinson’s disease specific phenotypes that can be observed in these midbrain organoids are more relevant for the actual situation in patients than those that are observed in homogenous two-dimensional cultures of single cell types. Furthermore, we are convinced that continued and noninvasive monitoring of Parkinson’s disease specific phenotypes will lead to a more detailed understanding of dynamic disease processes. The three objectives of the proposed research include a) the generation of three-dimensional organoids using induced pluripotent stem cells derived from Parkinson’s disease patients; b) to develop a computer-controlled fully automated miniaturized 3D midbrain-on-a-chip system containing embedded optical and electrical microsensors to investigate dynamic cell-to-cell and cell-tomatrix interactions; and c) the examination of patient specific 3D midbrains to determine disease specific phenotypes. These advanced and personalized disease models will be the basis for a more detailed understanding of disease processes, as well as for future screenings to modulate or treat the disease. |
Network | JPco-fuND |
Call | Neurodegenerative diseases: risk and protective factors, longitudinal cohort approaches and advanced experimental models |
Project partner
Number | Name | Role | Country |
---|---|---|---|
1 | University of Luxembourg | Coordinator | Luxembourg |
2 | Max-Planck-Institute for Molecular Biomedicine | Partner | Germany |
3 | AIT Austrian Institute of Technology | Partner | Austria |
4 | Erasmus MC | Partner | Netherlands |
5 | Technion | Partner | Israel |